By proceeding, you agree to our Terms of Use and Privacy Policy.
After his PhD thesis in biology and fellowship, Aloïse Mabondzo joined the CEA, the Life Science Division in May of 1998 as the leader of the Neurovascular Pharmacology Laboratory with a strong focus on in vitro blood-brain barrier modeling and pathophysiology of the brain. He developed “fully characterized in vitro screening tools” allowing the optimization of molecules under development for brain penetration and establishing the first human blood brain barrier (BBB) model expressing BBB properties in vivo. Several PhD and podt-doctoral positions have been part of his team. He has obtained numerous academic research grants. These financial supports have allowed and still make possible the development of research programs in neuroscience field. His current research intersts include creatine as a medicinal compound, creatine derived compounds with therepeutical effects, therapy of Tauopathy, Rasmussen diseases and neonatal ischemia. He is author or co-author of numerous articles in peer reviewed jounals, 4 patents.
Talks About #biology #neuroscience #healthresearch
Preferred Locations #Europe